Related Experiment Video
Updated: Sep 6, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Metamizole as a Rare Cause of Drug-Induced Liver Injury
Nevena Preveden1,2, Matthias E Liechti3, Tobias Oettl1
1Department of Internal Medicine, Gesundheitszentrum Fricktal, Rheinfelden, Switzerland.
Abstract:
Drug-induced liver injury (DILI) is a heterogenous entity with a wide range of pathogenetic mechanisms and clinical manifestations. DILI is a diagnosis of exclusion. Metamizole (dipyrone) is an analgesic increasingly used in Europe, but there is limited information on its adverse effects. We report the case of a 56-year-old man with acute fever, malaise and general deterioration. Onset of symptoms occurred 12 hours after intake of metamizole for shoulder pain. The patient's medical history was remarkable for three episodes of an inflammatory syndrome with hepatitis of unknown aetiology during the previous 3 years. However, retrospective enquiry showed each episode was preceded by metamizole intake shortly before symptom onset. Relevant differential diagnoses such as infection, vasculitis, autoimmune or metabolic diseases were excluded. Liver biopsy was compatible with DILI. Discontinuation of metamizole led to rapid clinical improvement and normalization of liver transaminases. Metamizole is a very rare and poorly known cause of DILI with only a few published case reports in the literature. Careful medical history taking is important to identify the causative agent. Prompt recognition and discontinuation of the drug is crucial. Patients must be informed to avoid this medication in future.
Learning Points:
Metamizole is a rare cause of drug-induced liver injury (DILI).Taking a systematic medical and drug history is crucial for diagnosing DILI.DILI is a diagnosis of exclusion.
Insights
Metamizole (dipyrone) is a rare cause of drug-induced liver injury (DILI). Prompt diagnosis and drug cessation are crucial for patient recovery and preventing future adverse events.
Area of Science:
- Hepatology
- Pharmacology
- Internal Medicine
Background:
- Drug-induced liver injury (DILI) presents diverse mechanisms and symptoms.
- Metamizole (dipyrone) use is increasing in Europe, with limited data on its hepatotoxicity.
- DILI is a diagnosis of exclusion, requiring thorough differential diagnosis.
Purpose of the Study:
- To report a case of DILI attributed to metamizole.
- To highlight the importance of detailed medical and drug history in DILI diagnosis.
- To emphasize the need for patient awareness regarding metamizole's potential adverse effects.
Main Methods:
- Case report of a 56-year-old male presenting with acute hepatitis.
- Exclusion of other potential causes of liver injury, including infections and autoimmune diseases.
- Liver biopsy confirming DILI, with subsequent cessation of metamizole.
Main Results:
- The patient experienced recurrent hepatitis episodes linked to metamizole intake.
- Liver biopsy confirmed drug-induced liver injury.
- Discontinuation of metamizole resulted in rapid clinical improvement and normalized liver enzymes.
Conclusions:
- Metamizole is identified as a rare cause of drug-induced liver injury.
- Systematic medical and drug history is critical for diagnosing DILI.
- Early recognition and withdrawal of the offending agent are essential for managing DILI.
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Drug Metabolism: Phase I Reactions
Drug Metabolism: Phase II Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

